Beneficial effect of oral semaglutide for type 2 diabetes mellitus in patients with metabolic dysfunction-associated steatotic liver disease: A prospective, multicentre, observational study.

Taeang AraiMasanori AtsukawaAkihito TsubotaTsunekazu OikawaToshifumi TadaKentaro MatsuuraToru IshikawaHiroshi AbeKeizo KatoAsahiro MorishitaJoji TaniTomomi OkuboMototsugu NagaoMasato IwabuKatsuhiko Iwakiri

Published in: Diabetes, obesity & metabolism (2024)

Oral semaglutide treatment for T2DM in patients with MASLD leads to an improvement in liver steatosis and injury, surrogate markers of fibrosis, diabetic status, and lipid profile, and reduces body weight.

Keyphrases

body weight
glycemic control
type diabetes
insulin resistance
oxidative stress
high fat diet
study protocol
cross sectional
wound healing
cardiovascular disease
metabolic syndrome
cardiovascular risk factors
skeletal muscle
high fat diet induced
smoking cessation